According to an article recently published in the journal Lung Cancer, the chemotherapy combination consisting of Eloxatin® (oxaliplatin) and Taxotere® (docetaxel) is well-tolerated and provides anticancer activity for patients with advanced non–small cell lung cancer.
Lung cancer remains the leading cause of cancer-related deaths in the United States. Non–small cell lung cancer (NSCLC) accounts for approximately 75–80% of all lung cancers: “non–small cell” refers to the type of cell within the lung where the cancer originated.
Chemotherapy with one or two agents remains the cornerstone of therapy for advanced, or metastatic, NSCLC. Advanced NSCLC refers to cancer that has spread from the lung to distant sites in the body. Since treatment is often aimed at extending duration of survival and improving quality of life for these patients, researchers continue to evaluate different chemotherapy combinations in order to identify the optimal regimen.
Researchers from the University of Miami recently conducted a clinical trial evaluating the combination of Eloxatin and Taxotere in 29 patients with advanced NSCLC.
- A partial regression of cancer occurred in 37% of patients.
- At one year, survival was 40%.
- At 18 months, survival was 18%.
- The most common severe side effects were low levels of red blood cells and high blood sugar levels.
The researchers concluded that treatment including Eloxatin/Taxotere is a well-tolerated and active regimen for the treatment of advanced NSCLC.
Patients with advanced NSCLC may wish to speak with their physician regarding their individual risks and benefits of different treatment options or participation in a clinical trial. Two sources of information regarding ongoing clinical trials include the National Cancer Institute (www.cancer.gov) and www.cancerconsultants.com.
Reference: Raez LE, Santos ES, Lopes G, et al. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non–small cell lung cancer (NSCLC). Lung Cancer. 2006;53:247-353.
Copyright © 2018 CancerConnect. All Rights Reserved.